Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial
Authors
Keywords
-
Journal
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2020-11-13
DOI
10.1093/jac/dkaa501
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment
- (2020) Hossein Poustchi et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Radiologic Management of COVID-19: Preliminary Experience of the Iranian Society of Radiology COVID-19 Consultant Group (ISRCC)
- (2020) Arash Mahdavi et al. Iranian Journal of Radiology
- Favipiravir, an antiviral for COVID-19?
- (2020) Eric A Coomes et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
- (2020) Yeming Wang et al. LANCET
- Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
- (2020) Jason D. Goldman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Remdesivir for the Treatment of Covid-19 — Preliminary Report
- (2020) John H. Beigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
- (2020) Bin Cao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China
- (2020) Ling Mao et al. JAMA Neurology
- Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
- (2020) Qingxian Cai et al. Engineering
- Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic
- (2020) Rodrigo Jácome et al. Scientific Reports
- Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial
- (2020) Anahita Sadeghi et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial
- (2020) Hamideh Abbaspour Kasgari et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19
- (2020) Gholamali Eslami et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started